Luven
diagnostic

Early Cancer Detection
is a Key to Successful Treatment

Luven
diagnostic

According to the World Health Organization:

Regardless of the rapid development of modern medicine and biology, here's disappointing statistics on cancer:

- Each year **8,000,000 people** worldwide die from cancer;
- **Every day 27,000 new patients** are diagnosed with cancer and this number is constantly growing;
- Due to the late diagnosis **more than half of cancer patients die**, because manifestations of the disease appear in advanced stages;
- In the last 10 years the number of oncology patients has increased by around 25% due to bad habits, such as smoking, drinking alcohol, obesity, unhealthy diet, pessimistic mentality etc.;
- The number of new cancer cases will rise by 70% within the next 20 years;

Luven
diagnostic

According to the World Health Organization:

As you know, the disease is also unfortunately found in kids.

Each year around 200,000 children worldwide are diagnosed with cancer 100,000 of which die, mainly due to late diagnosis.

Luven diagnostic

5-Year Relative Survival Rate by Stage

Pancreatic cancer



Only 9.7% are diagnosed at the local stage

Lung and Bronchus Cancer



Only 15.9% are diagnosed at the local stage

Ovarian Cancer



Only 14.8% are diagnosed at the local stage

Esophageal Cancer



Only 19.6% are diagnosed at the local stage

*data from cancer.gov

The average 5-year survival rate of cancer patients says that after treatment starting in stage 1 cancer – around 93% of patients survive; compared to only 13% surviving after treatment in stage 4.

If detected at the Early Stage, when there are NO visible symptoms, cancer can be cured without any complex aggressive therapies.

Luven
diagnostic

The Luven Diagnostic screening test created by the scientists of our company detects cancer at its early stages with the **accuracy of up to 96%** which is only comparable to biopsy. It can recognize the progressive disease when other diagnostic methods are helpless.

Luven diagnostic

History of the Method

The development started in early 1983 at the research institute, chair of genetics. Based on the cellular theory by Rudolf Virchow, a team of scientists was working on a diagnostic method by studying buccal cells (cells from the inside of the cheek) which are the fastest to respond to any changes in our body.

It took 28 years to collect a so-called “deviation album” which established a relationship between cell parameters and body conditions. It laid the basis for the Luven Diagnostic method the main idea of which is that any changes in the body manifest at the cellular level, including buccal cells. Thus, by examining 46 varying parameters of cells and their combinations our system allows, with a high degree of accuracy, to detect oncological diseases.

Ms. Galina Shchukina
Genetic scientist and
Cytologist

Mr. Alexander Shchukin
Nuclear Physicist
Chair of Experimental
Nuclear Physics

Luven diagnostic

Diagnostic procedure

1. A patient card is filled out in the computer program;

2. A buccal swab (a **painless swab** from the inside of the cheek) is carefully collected with a mouth spatula and placed under the microscope;

3. The program records a video from the microscope and transfers it to the processing center;

4. The received data get processed and analyzed by cell parameters (46) and their combinations

(e. g. cell shape, nuclear shape, cell and nuclear membranes, cytoplasmic inclusions and much more)



5. Within several minutes the program receives a printable report showing:

- cancer lesions in the body, if any;
- predisposition or liability to cancer;
- co-existing diseases according to the International Classification of Diseases

Luven
diagnostic

Features of our diagnostic method

No pain, discomfort or
side effects (non-invasive)

Quick test results
(within 15 minutes)

No radiation exposure

Early detection
(when there are no visible
symptoms yet)

No restriction
on the frequency of screening

1 test for any type of cancer
check several organs with one test

High diagnostic accuracy
at a low cost

Luven
diagnostic

Features of our diagnostic method

Portability

(space-saving equipment can be carried around and
used in areas with no hospitals or labs)

Luven diagnostic

Cancer Diagnostics Market Size



The global cancer diagnostics market size was valued at USD 124 billion in 2016 and is expected to grow at 7.2% CAGR over the forecast period

*grandviewresearch.com

Luven
diagnostic

Cancer Diagnostics Market Size

There's something more to this…

Luven is now expanding the market boundaries, since existing screening tests are pretty expensive and only recommended for patients with a risk of genetic predisposition and to elderly people.

The price of one test will vary from country to country depending on its GDP, roughly from $20 to $800. This will **make Luven screening test a mainstream**, such as a cholesterol test, for example.

The corporate market is huge, so that corporations with a big number of employees can simply put test rooms in their campuses and industrial buildings or even in offshore oil platforms.

Collaboration with insurance companies will allow them, among other things, to quickly run a health checkup.

Luven diagnostic

Cancer Diagnostics Market Size

We would like to highlight a **great scientific potential** of our method. Further, we can teach it not only to diagnose oncology, but also any other disease, provided that there are sufficient inputs.

Just imagine! You come to a clinic, undergo one painless test and, within 10 or 15 minutes, get a report showing all your diseases and medical specialists to visit.

In the near future, we are going to develop an intelligent home-use device designed to test any person anywhere in the world.

In addition, we also can enhance our method to **diagnose animals** which, unfortunately, cannot tell us about their complaints.

Competitors

Early Cancer Detection Companies

	Luven diagnostic	GRAIL (**raised $900M**)	**CancerSEEK**
Type	**Painless Buccal Swab**	Blood test	Blood test
Accuracy	96% lung cancer 50-60% blood and skin cancer* 80-95% other types	N/A	~70% 98% ovarian tumors 33% breast tumors
Method	**own patented method**	tests for tumor DNA	tests for tumor DNA + protein biomarkers
Ready to market	market by 2019	market by 2019	market by ????
Cost for a patient	**20 - 800$** (depending on the country and its GDP)	500$	500$

* as we don't have enough data about this types of cancer. Our system is easily taught and its diagnostic accuracy will only increase with the lapse of time.

Luven
diagnostic

Business model

The company will start selling sets of necessary equipment with software to labs, hospitals and physicians in private practice.

Tests will be read on the company servers, each test will be paid. The diagnosis price will vary from country to country. The lowest price will be based on the current GDP per capita.

The company services will cost 50% of the retail price. In this manner, we will ensure a balance between affordability of the diagnosis for the population and Company income.

Luven diagnostic

What we need money for

At present, to hit the biotechnology market, a company should have a huge amount of invested funds for conducting laboratory and clinical trials. Few big companies can actually afford it, let alone the startup process.

Since 1986 the data of more than 20 000 patients with oncology have been used.

Luven Diagnostic system was trained with the help of the data of 1 500 clinically confirmed diagnoses.

To start commercial adoption of Luven technology, clinically confirmed and documented data of 10 000 patients with oncology is required (proportionally for each type of cancer).

"Approved"
Chief Physician of Odessa
Regional Oncology Center
Prof. Dobrovolsky N.A.
« 15 » 08 2014

Clinical Trial Report

submitted for clinical trial:
hysical method in the diagnosis of malignant tumors.
sion date: G. V. Shchukina, N A Shchukin, 01.08.14
ical trial: Odessa Regional Oncology Center, 02.08.14

studies: 37
tion of the above specified method for the period from 01.07.14 to

nce of a tumor is confirmed) – 33 – (89,2%)
match of localization in organ systems – 33 - (89,2%)
(in need of further examination) – 1 – (2,7%)
ber of studies) – 3 – (8,1%)
esult therefore amounts to 89,2%.
f the implementation of this method (ambulant therapy period,
nability to work, disability reduction, economic effect, and other
ve the quality of treatment and diagnostic process and to shorten
l.
posals: To continue the monitoring and oncological diagnostics for
t results were inconclusive or negative.

Laboratory N.V. Makarova

Sciences,
r clinical trial A.M. Moskalenko

"Approved"
Deputy General
Director for Scientific
antineoplastic therapeutic
fitocenter "Phoenix"
N.A. Bogdan
06/17/14

Clinical Trial Report

1. Name of the proposal submitted for clinical trial:
   Cancer diagnostic method.
2. Submitted by/ submission date: N.A. Shchukin, 10.02. 2014
3. Place and date of clinical trial: Scientific antineoplastic therapeutic fitocenter "Phoenix"
   Total number of case studies: 100
4. Results of the application of the above specified method for the period from 10.02.14 to 30.05.14:
   Positive (number of case studies) – 96
   Inconclusive (number of case studies) – 0
   Inaccurate or incomplete analysis (number of case studies) – 4
   The positive result therefore amounts to 96%.
5. The expected effect of the implementation of this method (ambulant therapy period, period of temporary inability to work, disability reduction, economic effect, and other indicators) is to improve the quality of treatment and diagnostic process.
6. Observations and proposals: To continue the observation and testing.

Head of Laboratory of the Scientific
antineoplastic therapeutic fitocenter "Phoenix" Galina Shchukina

Person responsible for clinical trial
Candidate of Medical Sciences,
Oncologist Gynecologist, Skritskaya Tatyana

06/17/14

Luven diagnostic

What we need money for

First of all we need opening a research center in Austria, because Austrian clinical trails are recognized in all European union.

In addition, we need funds for:

- Debugging software for computer-assisted learning and automatic recognition of images transmitted from lab microscopes,
- Further studies, since the technology not only allows to detect cancer, but also other co-existing diseases;
- Marketing and advertising
- Legal costs
- Developing a (home) device that will allow to run diagnosis on the entire family at any time
- Other business-related activities directed at development

Luven diagnostic

How much money we need

$25M

Long Term Investment
Approximate payback period of the project – 3-4 years

Which includes:

- $13M for receiving the data of ~10 000 new clinically confirmed cancer diagnoses and its processing
- $3M for debugging software for computer learning (AI) and automatic recognition of images transmitted from lab microscopes
- $4M for clinical trials and the system’s certification
- $5M for other business-related activities directed at development (salary, servers, legal, marketing)

Luven
diagnostic

Investment prospects

Currently, **early cancer diagnostics market is absolutely unoccupied** and in fact only 2-3 companies are involved in this race and they announced they had some sort of results.



Our method is based on our own developments and exceeds all other methods of early diagnostics by many parameters.

If we collect enough funds and get involved in this race now, we will undoubtedly bite off the major part of the market and become the **leader of screening testing** all over the world.

Luven
diagnostic

Investment prospects



At the moment, our company has completed 90% of the project.

- We have already conducted studies and developed the entire procedure
- We have developed the software for training of our system
- We have developed the software for our future franchisees
- We have received patents in Ukraine and Russia
- We submitted an application to the WIPO that will secure our international reputation and will allow us to obtain more patents in various countries

Investment in our project will not only be a cure for a huge number of people, but also a tool for making money

Luven
diagnostic

Our mission is saving from death 1,000,000 people each year

Millions of people can save their lives if they get early diagnosis of possible health problems

Let’s do it together!

Luven diagnostic

Contacts

Feel free to contact me in any convenient way:

Grigoriy Evglevskiy
Telegram: https://t.me/system2
Skype: **gevglevskiy**
Email: grigoriy@luvenmed.io
WhatsApp/Voice: **+380 996441544**

Luven diagnostic

Links / Media

About method

https://www.youtube.com/watch?v=pd5aXL2tw9k

Diagnostic procedure

https://www.youtube.com/watch?v=TA0Q89LrP7E

WIPO/Patent

https://www.google.com/patents/WO2016089336A1?cl=en

https://luvenmed.io

please do not pay attention to the fact our ICO is active now – we are trying to raise funds with its help but the ICO does not go well due to our small-scale budget. And if we find an investor (perhaps, it is you!), we will stop our ICO, refund all the received investments and start working with him as our main investor.